Article
CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations.
Clinical and translational medicine - 1 Sept 2022
Tang Ling, Huang Hongming, Tang Yutong, Li Qing, Wang Jue, Li Dengju, Zhong Zhaodong, Zou Ping, You Yong, Cao Yang, Kong Yingjie, Guo Anyuan, Zhou Shu, Li Huimin, Meng Fankai, Xiao Yi, Zhu Xiaojian
Abstract excerpt
BACKGROUND: Chimeric antigen receptor T-cell (CAR-T) therapy for acute myeloid leukaemia (AML) has thus far been elusive, in part due to target restriction and phenotypic heterogeneity of AML cells. Mutations of the FMS-like tyrosine kinase 3 (FLT3) and DNA methyltransferase 3A (DNMT3A) genes are common driver mutations that present with a poor prognosis in AML patients. We found that AML patients with FLT3 or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.